Anhedonia, depression, and motor functionong in Parkinson's disease during treatment with pramipexole

Journal of Neuropsychiatry and Clinical Neurosciences

Volumn 17, Issue 2, 2005, Pages 214-220

  Lemke, Matthias R ^a   Brecht, H Michael ^b   Koester, Juergen ^b   Kraus, Peter H ^b   Reichmann, Heinz ^b  

^a Rhine Clinic Bonn   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE RECEPTOR STIMULATING AGENT; HYPERICUM PERFORATUM EXTRACT; HYPNOTIC AGENT; LEVODOPA; MONOAMINE OXIDASE INHIBITOR; NEUROLEPTIC AGENT; NORADRENALIN UPTAKE INHIBITOR; PRAMIPEXOLE; SEROTONIN UPTAKE INHIBITOR; TETRACYCLIC ANTIDEPRESSANT AGENT; TRICYCLIC ANTIDEPRESSANT AGENT; ANTIPARKINSON AGENT; BENZOTHIAZOLE DERIVATIVE; PRAMIPEXOL; THIAZOLE DERIVATIVE;

ADD ON THERAPY; ADULT; AGED; ANHEDONIA; ARTICLE; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DEPRESSION; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MORBIDITY; MOTOR DYSFUNCTION; MOTOR PERFORMANCE; PARKINSON DISEASE; PRIORITY JOURNAL; AGING; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFECT; PHYSIOLOGY; PROSPECTIVE STUDY; PSYCHOLOGICAL ASPECT; PSYCHOLOGICAL RATING SCALE; PSYCHOMOTOR PERFORMANCE;

ACTIVITIES OF DAILY LIVING; AGED; AGING; ANTIPARKINSON AGENTS; BENZOTHIAZOLES; DEPRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; PARKINSON DISEASE; PROSPECTIVE STUDIES; PSYCHIATRIC STATUS RATING SCALES; PSYCHOMOTOR PERFORMANCE; THIAZOLES;

EID: 85047693394     PISSN: 08950172     EISSN: None     Source Type: Journal    
DOI: 10.1176/jnp.17.2.214     Document Type: Article

References (21)

1. Kuopio AM, Marttila RJ, Helenius H, et al: The quality of life in Parkinson's disease. Mov Disord 2000; 15:216-223
2. Heinz A, Schmidt LG, Reischies FM: Anhedonia in schizophrenic, depressed, or alcohol-dependent patients: neurobiological correlates. Pharmacopsychiatry 1994; 27 (Suppl) 1:7-10
3. Braak H, Braak E: Pathoanatomy of Parkinson's disease. J Neurol 2000; 247 (Suppl)2:II3-10
4. Heinz A, Dufeu P, Kuhn S, et al: Psychopathological and behavioral correlates of dopaminergic sensitivity in alcohol-dependent patients. Arch Gen Psychiatry 1996; 53:1123-1128
5. Maj J, Rogoz Z, Skuza G, et al: The behavioural effects of pramipexole, a novel dopamine receptor agonist. Eur J Pharmacol 1997; 324:31-37
6. Willner P, Lappas S, Cheeta S, et al: Reversal of stress-induced anhedonia by the dopamine receptor agonist, pramipexole. Psychopharmacology (Berl) 1994; 115:454-462
7. Snaith RP: Identifying depression: the significance of anhedonia. Hosp Pract 1993; 28:55-60
8. Lemke MR, Puhl P, Koethe N, et al: Psychomotor retardation and anhedonia in depression. Acta Psychiatr Scand 1999; 99:252-256
9. Taylor AE, Saint-Cyr JA: Depression in Parkinson's disease: reconciling physiological and psychological perspectives. J Neuropsychiatry Clin Neurosci 1990; 2:92-98
10. Shehan DV, Lecrubier Y, Sheehan KH, et al: The Mini-International Neuropsychiatric Interview (MINI): the development and validation of a structered psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 59(S20):22-33, 1998
11. Simpson GM, Angus JWS. A rating scale for extrapyramidal side effects. Acta Psychiat Scand 1970; 212:S11-19
12. Hoehn MM, Yahr MD: Parkinsonism: onset, progression and mortality. Neurol 1967; 17:427-442
13. Rabey JM, Bass H, Bonuccelli U, et al: Evaluation of the short parkinson's evaluation scale: a new friendly scale for the evaluation of Parkinson's disease in clinical drug trials. Clin Neuropharmacol 1997; 20:322-337
14. Franz M, Lemke MR, Meyer T, et al: German version of the Snaith-Hamilton Pleasure Scale (SHAPS-D). anhedonia in schizophrenic and depressive patients. Fortschr Neurol Psychiatr 1998; 66:407-413
15. Snaith RP, Hamilton M, Morley S, et al: A scale for the assessment of hedonic tone the Snaith-Hamilton Pleasure Scale. Br J Psychiatry 1995; 167:99-103
16. Mayberg HS, Solomon DH: Depression in parkinson's disease: a biochemical and organic viewpoint. Adv Neurol 1995; 65:49-60
17. Cummings JL: Depression and Parkinson's disease: a review. Am J Psychiatry 1992; 149:443-454
18. Yamamoto M: Depression in Parkinson's disease: its prevalence, diagnosis, and neurochemical background. J Neurol 2001;248 (Suppl) 3:III5-11
19. Richard IH, Kurlan R: A survey of antidepressant drug use in Parkinson's disease. Parkinson study group. Neurol 1997; 49:1168-1170
20. Schrag A, Jahanshahi M, Quinn N: What contributes to quality of life in patients with Parkinson's disease? J Neurol Neurosurg Psychiatry 2000; 69:308-312
21. Corrigan MH, Denahan AQ, Wright CE, et al: Comparison of pramipexole, fluoxetine, and placebo in patients with major depressive disorder. Depress Anxiety 2000; 11:58-65